SNRIs Compatible with Pain Medications and Muscle Relaxants

Primary Recommendation: Duloxetine

The American Geriatrics Society recommends duloxetine as the preferred SNRI for use with pain medications and muscle relaxants, due to its strong evidence for safety and efficacy in chronic pain conditions, and it can be safely combined with opioids, NSAIDs, and muscle relaxants when appropriate monitoring is in place 1, 2, 3
Duloxetine (60-120 mg/day) is FDA-approved for multiple pain conditions, including diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, and chronic low back pain, and can be safely co-administered with opioids as part of multimodal pain management, often reducing opioid requirements 1, 2, 4, 5
The National Comprehensive Cancer Network recommends duloxetine as an adjuvant analgesic that can be co-administered with opioids to enhance analgesia or reduce opioid requirements, and it is compatible with NSAIDs for myofascial and skeletal pain when used together 1, 4
The American Geriatrics Society notes that duloxetine has a more favorable safety profile compared to tricyclic antidepressants, particularly regarding anticholinergic effects and cardiac conduction issues 3

The American Diabetes Association recommends venlafaxine (150-225 mg/day) as an effective treatment for painful diabetic neuropathy, and it can be used with pain medications, but cardiovascular adverse events, including dose-dependent hypertension, limit its use, requiring blood pressure monitoring 2
The American Geriatrics Society recommends monitoring blood pressure before initiating SNRI therapy, especially with venlafaxine and levomilnacipran, and measuring blood pressure periodically 2

The National Comprehensive Cancer Network recommends SNRIs as adjuvant analgesics that can be co-administered with opioids to enhance analgesia or reduce opioid requirements, and this combination is part of standard multimodal pain management strategies 1, 4, 5, 7
The American Society of Anesthesiologists notes that SNRIs can be safely combined with NSAIDs for treatment of myofascial, skeletal pain, myalgias, and arthralgias, and with muscle relaxants (diazepam, lorazepam, metaxalone, cyclobenzaprine) for skeletal pain and muscle spasm 1, 4, 8
The American Geriatrics Society recommends caution when combining SNRIs with muscle relaxants, as both can cause sedation and dizziness, and monitoring for increased bleeding risk when combining SNRIs with NSAIDs or aspirin, as both affect hemostasis 8

The American Geriatrics Society recommends never discontinuing SNRIs abruptly, but rather tapering gradually to prevent withdrawal syndrome, and monitoring for serotonin syndrome when combining SNRIs with tramadol, fentanyl, meperidine, or other serotonergic agents 3, 6
The American Heart Association recommends measuring blood pressure before initiating SNRI therapy, especially with venlafaxine and levomilnacipran, and monitoring periodically 2

The American Geriatrics Society recommends starting duloxetine at 30 mg once daily for one week, then increasing to 60 mg daily, and assessing efficacy after at least 4 weeks at therapeutic dosage, and never discontinuing abruptly, but rather tapering gradually to prevent withdrawal syndrome 1, 3, 6